A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.

  title={A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.},
  author={James G. Waxmonsky and Daniel A. Waschbusch and Opeoluwa Akinnusi and William E. Pelham},
  journal={Journal of child and adolescent psychopharmacology},
  volume={21 1},
OBJECTIVE This secondary analysis examined the efficacy and tolerability of atomoxetine (ATX) dosed once (QD) versus twice (BID) daily in 55 children aged 6-12 with attention-deficit/hyperactivity disorder (ADHD). METHODS The original 8-week trial was designed to assess the benefits of adding behavioral therapy to ATX. In it, all subjects were treated openly with ATX, with 50% randomly assigned to additional behavioral treatments. Every subject was started on QD dosing with a target dose of 1… 

Figures and Tables from this paper

The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research

Overall, these papers demonstrate that atomoxetine is an effective treatment for the core ADHD symptoms, and improves functional outcomes and quality of life, in various pediatric populations with ADHD, and it is important that the clinician sets appropriate expectations with regard to the likelihood of a gradual response, which often builds over time.

Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.

GXR adjunctive to a psychostimulant significantly reduced oppositional symptoms in subjects with ADHD and a suboptimal response to psychostIMulant alone.

The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research

A comprehensive review of publications that addressed one or more of seven major safety topics relevant to atomoxetine treatment of children and adolescents diagnosed with ADHD found 15 papers about suicidality, three about aggression/hostility, seven about psychosis/mania, and six about seizures.

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder

An updated summary of the literature on atomoxetine is provided, particularly in relation to findings on the short- and long-term safety of atomoxettine in children and adolescents arising from recent large longitudinal cohort studies.

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

In the studies identified and assessed in this review, atomoxetine did not appear to exacerbate any of the comorbid conditions and could, therefore, be an important therapy choice for the treatment of ADHD in the presence ofComorbid disorders.

A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder.

  • L. BriarsTimothy J. Todd
  • Psychology, Medicine
    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
  • 2016
This review focuses on the clinical use of psychostimulant medication in children and adolescents and the pharmacodynamic and pharmacokinetic differences between the newest long-acting formulations as well as commonly encountered adverse drug reactions.

Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety

Using minimum 6-week clinical trial criteria, atomoxetine may demonstrate similar efficacy to methylphenidate comparing reduction in core ADHD symptoms in meta-analysis, although the diversity of the data makes interpretation complex.

Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety

Basic clinical pharmacology of stimulant and nonstimulant attention-deficit/hyperactivity disorder medications and selective serotonin reuptake inhibitors is provided to serve as a primer for the general pediatrician.

Electroencephalogram activity in attention-deficit hyperactivity disorder

It is found that the score of the KSADS-PL rating scale was significantly decreased in ADHD patients after treatment in both pharmacotherapy groups and there was no significant difference in EEG between both ADHD children before and after treatment.

Pharmacotherapy for attention-deficit/hyperactivity disorder

  • Bongseog Kim
  • Medicine, Psychology
    Journal of the Korean Medical Association
  • 2019
Clinicians should try to develop rapport with patients and their caregivers to increase the likelihood that they will follow the diagnostic process and treatment, and the use of long-acting stimulants is increasing.



Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

Once-daily administration of atomoxetine is an effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD) as assessed by investigator, parent, and teacher ratings.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Once-daily administration of atomoxetine in the morning provided safe, rapid, continuous, symptom relief that lasted not only into the evening hours but also into the morning hours.

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

  • M. WeissR. Tannock A. Allen
  • Medicine, Psychology
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2005
This study extends previous results based on parent reports showing that once-daily administration of atomoxetine is safe and effective in improving ADHD symptoms in children and demonstrates that outcomes at school are similar when symptoms are reported by teachers.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Among children and adolescents aged 8 to 18, atomoxetine was superior to placebo in reducing ADHD symptoms and in improving social and family functioning symptoms.

High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.

In both studies, continued treatment, whether at a higher dose or the previous dose, was associated with improved outcomes in patients who demonstrated incomplete/inadequate response to acute ADHD treatment, although without a placebo arm, it cannot rule out the possibility that expectancy played a role in symptom improvement.

Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.

Atomoxetine improved ADHD symptoms and classroom functioning as measured by parents, teachers, and direct observation and was associated with significant improvements in ADHD and oppositional defiant disorder symptoms at home and school and enhanced functioning in both domains.

Once-Daily Atomoxetine for Treating Pediatric Attention-Deficit/Hyperactivity Disorder: Comparison of Morning and Evening Dosing

Morning dosing was superior to evening dosing on some efficacy measures and Evening dosing showed greater tolerability with significantly more patients receiving morning atomoxetine reporting at least 1 adverse event than those receiving evening atomxetine.

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

All 3 lisdexamfetamine doses were significantly more effective than placebo in the treatment of adults with ADHD, with improvements noted within 1 week.

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Youths with ADHD and comorbid ODD showed statistically significant improvement in ADHD, ODD, and quality-of-life measures, although the COMorbid group may require higher doses of atomoxetine.

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

When starting atomoxetine, the risk of adverse events within the first few weeks of treatment may be lower if patients are dosed twice daily and titrated to the 1.2 mg/kg/day total daily dose over the first week.